PCVX Vaxcyte Inc

Price (delayed)

$19.5

Market cap

$1.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.19

Enterprise value

$957.79M

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious ...

Highlights
PCVX's quick ratio has surged by 110% year-on-year and by 43% since the previous quarter
Vaxcyte's equity has increased by 27% QoQ and by 10% YoY
The EPS has decreased by 13% from the previous quarter but it has increased by 12% YoY
The net income has contracted by 41% YoY and by 18% from the previous quarter
The debt is up by 34% since the previous quarter

Key stats

What are the main financial stats of PCVX
Market
Shares outstanding
58.31M
Market cap
$1.14B
Enterprise value
$957.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.05
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$117.84M
EBITDA
-$112.54M
Free cash flow
-$144.09M
Per share
EPS
-$2.19
Free cash flow per share
-$2.5
Book value per share
$6.38
Revenue per share
$0
TBVPS
$7
Balance sheet
Total assets
$402.72M
Total liabilities
$43.17M
Debt
$22.41M
Equity
$359.54M
Working capital
$314.97M
Liquidity
Debt to equity
0.06
Current ratio
12.56
Quick ratio
12.28
Net debt/EBITDA
1.59
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-32.8%
Return on equity
-37.2%
Return on invested capital
-58.7%
Return on capital employed
-31.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCVX stock price

How has the Vaxcyte stock price performed over time
Intraday
-6.7%
1 week
-3.42%
1 month
-25.57%
1 year
-16.7%
YTD
-18.03%
QTD
-19.25%

Financial performance

How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$119.75M
Net income
-$117.84M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has decreased by 41% YoY and by 16% QoQ
The net income has contracted by 41% YoY and by 18% from the previous quarter

Growth

What is Vaxcyte's growth rate over time

Valuation

What is Vaxcyte stock price valuation
P/E
N/A
P/B
3.05
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 13% from the previous quarter but it has increased by 12% YoY
Vaxcyte's equity has increased by 27% QoQ and by 10% YoY
The P/B is 24% lower than the last 4 quarters average of 4.0

Efficiency

How efficient is Vaxcyte business performance
PCVX's ROIC has soared by 95% year-on-year but it is down by 8% since the previous quarter
Vaxcyte's return on equity has shrunk by 58% YoY and by 15% QoQ
PCVX's ROA has shrunk by 57% YoY and by 16% QoQ

Dividends

What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCVX.

Financial health

How did Vaxcyte financials performed over time
Vaxcyte's current ratio has surged by 113% YoY and by 41% QoQ
PCVX's quick ratio has surged by 110% year-on-year and by 43% since the previous quarter
The debt is 94% smaller than the equity
The debt is up by 34% since the previous quarter
Vaxcyte's equity has increased by 27% QoQ and by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.